Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)

This solicitation, ARPA-H-SOL-25-122 (THRIVE), seeks proposals for high-impact solutions to challenging health problems, accelerating better health outcomes. Evaluation will focus on technical merit, potential contribution to the ARPA-H mission (including future R&D, commercial, and clinical applications addressing unmet biomedical needs), proposer capabilities and experience, and cost realism. A critical requirement is a good faith representation of ownership or appropriate licensing rights to all intellectual property (IP) used in the proposed effort, which will be detailed in a full proposal. Proposers must align their quantitative and qualitative success criteria with the program objectives and associated metrics outlined in Table 1, demonstrating how their work will achieve satisfactory progress and warrant continued funding within the THRIVE program.

Notice ID

4bb23a768de04d54aa2300063f52b523

Solicitation Number

ARPA-H-SOL-25-122

NAICS Code

541714

Classification Code

AN13